Tobias Welte, ERS 2020 – COVID-19 Vaccines and Early Trials
Access all of the content
It was a pleasure to meet with Prof. Tobias Welte (Medizinische Hochschule, Hannover, Germany), following his keynote presentation, to continue the discussion around COVID-19 management, current vaccine approaches and promising agents in clinical development.
Questions
1. What are the major obstacles to be overcome in the investigation of management and preventative strategies for COVID-19? (0:37)
2. In your opinion, what are the most promising agents in clinical development for COVID-19 treatment? (2:47)
3. What progress has been made in the development of monoclonal antibody therapies? (5:14)
4. Could you give us a brief overview of the status of the major vaccine trials worldwide? (6:18)
5. What have we learned in terms of improving the efficiency of vaccine studies? (9:23)
Speaker disclosure: Tobias Welte has received research grants from the DFG, BMBF, EU, and WHO. He has also received lecture fees from AstraZeneca, Basilea, Biotest, Bayer, Boehringer, Berlin Chemie GSK, Infectopharm, MSD, Novartis, Pfizer, Roche and acted as an advisory board member for AstraZeneca, Basilea, Biotest, Bayer, Boehringer, Gilead, GSK, Janssens, Novartis, Pfizer and Roche.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ERS International Congress 2020.
